Abstract Number: 113 • 2018 ACR/ARHP Annual Meeting
Epigenetic Changes in Dermal Fibroblasts By Inhibition of DOT1L Affect Cell Proliferation and Cell Cycle, but Have No Direct Effects on Collagen Deposition in in Vitro and In Vivo models of Fibrosis
Background/Purpose: Fibrosis is a key feature of systemic sclerosis, a devastating disease that is not well understood. The role of epigenetic factors in the pathophysiology…Abstract Number: 115 • 2018 ACR/ARHP Annual Meeting
CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both…Abstract Number: 119 • 2018 ACR/ARHP Annual Meeting
Targeting Dysregulated CD38/NAD+ Homeostasis Mitigates Multiple Organ Fibrosis
Background/Purpose: Persistent myofibroblast activation underlies unresolving multi-organ fibrosis in systemic sclerosis (SSc). We had shown that fibrosis is associated with reduced expression of NAD-dependent sirtuins…Abstract Number: 128 • 2018 ACR/ARHP Annual Meeting
Inhibition of Prolyl-tRNA Synthetase As a Novel Therapeutic Target for Systemic Sclerosis
Background/Purpose: Prolyl-tRNA synthetase (PRS), a member of aminoacyl tRNA synthetases (ARS), is an enzyme that conjugates amino acid proline to its tRNA to generate prolyl-tRNA…Abstract Number: 1023 • 2018 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis
Background/Purpose: In bleomycin-induced model of systemic fibrosis and patients with systemic sclerosis, plasmacytoid DC (pDC) are unaffected or reduced systemically (spleen/peripheral blood) but they increase…Abstract Number: 1899 • 2018 ACR/ARHP Annual Meeting
Down-Regulation of RNA Processing Protein CFIm25 Amplifies Skin Fibrosis By up-Regulating Pro-Fibrotic Transcripts/Proteins in Systemic Sclerosis
Background/Purpose: Persistent myofibroblast activation and associated excessive extracellular matrix protein deposition are hallmarks of systemic sclerosis (SSc). However, the mechanisms that account for this excessive fibrotic response remain…Abstract Number: 1901 • 2018 ACR/ARHP Annual Meeting
Reduced SPAG17 Expression Links Dysfunctional Cilia, Morphogen Signaling Activation and Multiple Organ Fibrosis: Novel Target for Systemic Sclerosis
Background/Purpose: Persistent myofibroblast activation driving progressive fibrosis is the defining hallmark of systemic sclerosis (SSc). Uniquely, fibrosis in SSc affects the skin, heart, lungs and…Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…Abstract Number: 760 • 2017 ACR/ARHP Annual Meeting
Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis
Background/Purpose: Long noncoding RNAs (lncRNAs) represent a class of transcripts longer than 200 nucleotides that are not translated into proteins. In recent years, antisense (AS)…Abstract Number: 1927 • 2017 ACR/ARHP Annual Meeting
Anti-Fibrotic Mechanisms of Endostatin-Derived Peptide Are the Result of Reduction in Pro-Fibrotic Mediators and Promotion of Extracellular Matrix Degradation
Background/Purpose: Fibrotic disorders such as systemic sclerosis (SSc) result in end-stage organ failure and loss of function, consequently causing high morbidity and mortality. We recently…Abstract Number: 2688 • 2017 ACR/ARHP Annual Meeting
Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Background/Purpose: Biomarkers that can monitor the fibrotic burden will aid in trial enrichment and personalized health care in SSc. SSc is associated with internal organ…Abstract Number: 3174 • 2016 ACR/ARHP Annual Meeting
Apremilast Attenuates the Fibrogenic Phenotype of Dermal Fibroblasts from Patients with Systemic Sclerosis, Contributing to the Prevention of the Progression of Experimental Dermal Fibrosis
Background/Purpose: Systemic sclerosis (SSc) is a chronic fibrosing disorder that affects the skin and other internal organs. Inflammation, vasculopathy and fibrosis at the affected area…Abstract Number: 805 • 2016 ACR/ARHP Annual Meeting
HLA Class II Functional Motifs Associated with Severe Systemic Sclerosis (SSc) and Sclerotic Graft Versus Host Disease (sclGVHD): The Shared Epitopes of Fibrosis
Background/Purpose: Single Nucleotide polymorphisms within the HLA region have been strongly associated with the occurrence of SSc and sclGVHD. However, specific studies on the amino…Abstract Number: 810 • 2016 ACR/ARHP Annual Meeting
Microrna-125b As a Potential Anti-Fibrotic and Anti-Apoptotic Regulator in Systemic Sclerosis
Background/Purpose: MicroRNAs (miRs) are a class of small, noncoding RNAs that regulate many biological processes. Some microRNAs are involved in skin fibrosis. Here, we aimed…Abstract Number: 816 • 2016 ACR/ARHP Annual Meeting
Clinical Response to Treatment with Belimumab and Mycophenolate Mofetil Is Associated with Decrease in B Cell, TGF-β and PDGF Signaling in Systemic Sclerosis
Background/Purpose: While B cell signaling is thought to be important in the pathogenesis of systemic sclerosis (SSc), the experience with B cell targeting therapies in…